Gyre Therapeutics (GYRE) Projected to Post Quarterly Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) is expected to be announcing its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of $0.04 per share and revenue of $23.50 million for the quarter.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03). Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million.

Gyre Therapeutics Stock Performance

NASDAQ:GYRE opened at $9.71 on Monday. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $19.00. The stock has a market cap of $908.97 million, a price-to-earnings ratio of 194.20 and a beta of 1.93. The business has a fifty day moving average of $11.31 and a 200-day moving average of $12.20.

Insider Transactions at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 36,054 shares of company stock valued at $407,317. 19.52% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE grew its stake in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,937 shares of the company’s stock after purchasing an additional 1,996 shares during the period. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 as of its most recent SEC filing. Institutional investors own 23.99% of the company’s stock.

Analyst Ratings Changes

Separately, Noble Financial started coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.